A Phase III randomised, double-blind, multicentre study to evaluate the safety and efficacy of 1592U89 (abacavir) in human immunodeficiency virus 1-infected patients with aquired immune deficiency syndrome dementia complex

2013 ◽  
Author(s):  
Bruce Brew
Sign in / Sign up

Export Citation Format

Share Document